SpringWorks Therapeutics, Inc.
SWTXNASDAQHealthcare
$46.99
+$0.01(+0.02%)
Market Cap$3.5B
P/E Ratio—
52W High$62
52W Low$28.21
SpringWorks Therapeutics, Inc. (SWTX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SWTX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.26B) | ($0.33B) | ($0.28B) | ($0.17B) | ($0.05B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.11B | $0.09B | $0.07B | $0.04B | $0.01B |
| Change in Working Capital | ($0.04B) | ($0.00B) | $0.04B | $0.01B | $0.00B |
| Net Cash from Operations | ($0.18B) | ($0.22B) | ($0.16B) | ($0.13B) | ($0.03B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.01B) | ($0.01B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.29B) | ($0.58B) | ($0.48B) | ($0.31B) | ($0.45B) |
| Sales of Investments | $0.38B | $0.62B | $0.28B | $0.39B | $0.03B |
| Net Cash from Investing | $0.06B | $0.03B | ($0.22B) | $0.08B | ($0.42B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.01B) | ($0.00B) | ($0.00B) | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.00B | $0.30B | $0.34B | $0.00B | $0.27B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.18B) | ($0.23B) | ($0.17B) | ($0.13B) | ($0.03B) |
| FCF Margin %(computed) | -93.98% | — | — | — | -93.81% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more SpringWorks Therapeutics, Inc. data
About SpringWorks Therapeutics, Inc. (SWTX) Cash Flow Statement
SpringWorks Therapeutics, Inc. generated operating cash flow of ($0.18B) and free cash flow of ($0.18B) for 2024 — a FCF margin of -93.98%. Capital expenditure was ($0.00B).
Frequently asked questions
SWTX · 4 questionsSpringWorks Therapeutics, Inc. generated free cash flow of ($0.18B) for 2024, up 21.8% year-over-year.
SWTX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10